Peroxisome proliferator-activated receptor gamma receptor (PPARγ)

The Peroxisome proliferator-activated receptor gamma receptor (PPARγ) is a nuclear receptor and transcription factor that regulates multiple aspects of fatty acid metabolism, adipogenesis, insulin sensitivity, and immune responses. It is a ligand-activated protein found primarily in adipose tissue, colon, and macrophages, where it serves as a central regulator of metabolic homeostasis. PPARγ functions by binding to specific DNA elements as a heterodimer with the retinoid X receptor (RXR), modulating expression of genes involved in adipocyte differentiation, lipid storage, and glucose metabolism. Clinical drugs targeting PPARγ (mainly thiazolidinediones) have been used to treat type 2 diabetes, but carry notable safety risks such as weight gain and heart failure. Structurally, PPARγ contains modular domains (N-terminal, DNA-binding, ligand-binding), and the ligand binding pocket is large and promiscuous, allowing interactions with a variety of endogenous and synthetic ligands. It is a prominent target in efforts to treat metabolic diseases, inflammation, and certain cancers.

Other names

PPAR gammaPPARGNR1C3 (nuclear receptor subfamily 1, group C, member 3)Glitazone reverse insulin resistance receptorPeroxisome proliferator-activated receptor γHuman PPAR-gamma (hPPAR-gamma)

Agonists: Bind to ligand binding domain to activate PPARγ, promoting gene transcription associated with improved insulin sensitivity, adipogenesis, and anti-inflammatory effects Partial agonists: Bind but only partially activate or modulate the receptor's transcriptional activity (potentially fewer side effects than full agonists) Antagonists/inverse agonists: Bind to receptor and inhibit or repress gene transcription by stabilizing conformations that interact with corepressors Modulation of coactivator and corepressor binding (allosteric effects)